Leitung: Dr. Friedrich Thienemann (MD, DTMPH, MScIH)
Die Arbeitsgruppe General Medicine & Global Health (GMGH) ergänzt ambulante und stationäre Patientenversorgung mit Erfahrungen aus dem Bereich Global Health. Mit Hilfe der Arbeitsgruppe Global Health sollen Forschungsprojekte bereits während des Medizinstudiums verankert werden und so zu einer Berufsperspektive werden.
Unser Klinisches Trainingsprogramm & Forschungspartnerschaften mit der University of Cape Town (UCT) gibt Studierenden sowie Assistenzärztinnen und Assistenzärzten die Möglichkeit, frühzeitig Erfahrungen in der klinischen Forschung zu sammeln und an internationalen Austauchen teilzunehmen. Damit werden medizinische Ausbildung und die anschliessende Facharztausbildung durch das interessante und heute extrem relevante Gebiet Global Health ergänzt. Die nächste Generation von Ärztinnen und Ärzten sammelt so wertvolle interkulturelle Erfahrungen, vernetzt sich frühzeitig international, lernt andere Gesundheitssystemen kennen und ergänzt eine solide klinische Ausbildung. Somit stellen Universität Zürich und Universitätsspital Zürich sicher, dass die hier ausgebildeten Internisten globale Aspekte mit in Ihre Karrieren einbeziehen.
Südafrika und Schweiz – Ein Team, zwei Standorte
Die Arbeitsgruppe General Medicine & Global Health (GMGH) hat zwei Standorte. In der Schweiz ist GMGH in der Klinik und Poliklinik für Innere Medizin am Universitätsspital Zürich und Universität Zürich verankert. In Südafrika ist GMGH im Hatter Institute for Cardiovascular Research, Department of Medicine der University of Cape Town angegliedert.
Team
Dr. Friedrich Thienemann – Direktor GMGH / Chief
Principal Investigator
Dr. Sandra Mukasa – Direktorin GMGH UCT/ Local Principal
Investigator (Südafrika)
Dr. Samy Hassan – Assistenzarzt am USZ, Scientist und
PET/CT Analyst @PredictTB @StatinTB
Christian Elsener – Doktorrand zum Thema Mortalität
und Pneumonie
Klinisches
Trainingsprogramm
Unser klinisches Trainingsprogramm ist als Observership
aufgebaut. Ärztinnen und Ärzte sollen für zwei Wochen am Groote SchuurKrankenhaus in Südafrika, respektive Universitätsspital Zürich, am Klinikalltag
der Inneren Medizin teilnehmen. Im Mai 2019 hat das erste Team vom Universitätsspital
Zürich – ein Assistenzarzt und eine Oberärztin unserer Klinik – das Groote
Schuur Krankenhaus für zwei Wochen besucht.
Forschungspartnerschaften
– Unsere Forschungsprojekte (in englischer Sprache)
Research focus: Infectious diseases and interaction with
non-communicable diseases
-
Intervening along the spectrum of tuberculosis
- HIV and cardiovascular disease
- Tuberculosis and cardiovascular disease
- Post-tuberculosis lung disease
StatinTB - Preventing TB relapse and chronic lung
disease
StatinTB
is funded by the second European and Developing Countries Clinical Trials
Partnership (EDCTP2) and will receive € 5 million over the duration of four
years starting in January 2019.
Protocol title: Preventing TB
relapse and chronic lung disease: A proof-of-concept, double-blinded,
randomized, placebo-controlled trial to evaluate the safety and efficacy of
atorvastatin to reduce inflammation after TB treatment completion in
HIV-infected and HIV-uninfected adults measured by FDG-PET/CT. (StatinTB).
The primary objective is to
compare persistent lung inflammation measured by total lung glycolysis (TLG) on
PET/CT after 12 weeks of 40 mg atorvastatin therapy and placebo. If successful
this trial will have proven that statins as Host Directed Therapy (HDT) can be
safe and effective adjunctive therapy to TB treatment in general and further
efficacy trials can be undertaken to translate the results of this trial into
reduced TB relapse rate and reduced post-TB chronic lung disease, thus
decreased long-term TB-related morbidity.
Chief Principal Investigator: Dr.
Friedrich Thienemann
Local Principal Investigator: Dr
Sandra Mukasa
UCT ethics committee number:
675/2019
ClinicalTrials.gov number:
NCT04147286
Website
PredictTB
PredictTB is a five-year project financed by a variety of international funders and implemented by American, African, Asian and European partners, that aims to shorten the treatment times of tuberculosis (TB) in drug-sensitive patients through individualized therapy. Coordinated by Prof. Clifton Barry from the US National Institutes of Health and Prof. Gerhard Walzl from Stellenbosch University in South Africa. The project will implement a prospective, randomized, no inferiority phase 2b clinical trial, enrolling and following-up 620 patients with drug sensitive pulmonary TB in five collaborating sites in Cape Town, South Africa and four sites in Henan Province, China. Over the next five years, the project team will evaluate a set of criteria to reduce TB treatment times using data from scans, assays and cultures to evaluate inflammation and lung pathology, to test for the sustained presence of bacteria and to determine which patients are eligible for shortened treatment.
Principal Investigator: Prof. Clifton Barry
South African Principal Investigator: Prof Gerhard Walzl
University of Zurich is part of the EDCTP consortium with Dr Friedrich Thienemann as Principal Investigator
UCT ethics committee number: 464/2016
ClinicalTrials.gov number: NCT02821832
Website
HIV & Cardiovascular Disease (HIV & Heart)
From a global perspective, cardiovascular disease (CVD) in human immunodeficiency virus (HIV) may result from cardiac involvement upon presentation of opportunistic infections in the presence of advanced immunosuppression, be a consequence of HIV-induced immune activation or derive from antiretroviral therapy-associated dyslipidemia and insulin resistance. HIV-associated cardiomyopathy and HIV-associated pulmonary hypertension are the most common cardiac manifestations in HIV. This study is investigating cardiovascular disease in a health HIV-infected cohort in Cape Town using Echocardiography and cardiac biomarkers.
Principal investigator: Prof Mpiko Ntseke
Lead investigator: Dr Friedrich Thienemann
UCT ethics committee number: 337/2013
HIV-associated pulmonary hypertension
Epidemiology, etiology, management and outcome data for various forms of pulmonary hypertension (PH) in Africa are scarce. A prospective, multinational cohort registry of 220 consecutive patients (97% of African descent) from 9 specialist centers in 4 African countries. The antecedents, characteristics and management of newly diagnosed PH plus 6-month survival were studied. We are currently investigator the contribution of HIV to the burden of PH in Africa.
Co-Principal investigators: Prof Karen Sliwa and Dr Friedrich Thienemann
UCT ethics committee number: 337/2013
ClinicalTrials.gov number: NCT02265887
